Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study is a multicentre, international, randomized controlled trial of tranexamic acid (TXA) versus placebo and, using a partial factorial design, of a perioperative hypotension-avoidance versus hypertension-avoidance strategy.
The POISE-3 study is a 10,000 patient, multicentre, international, non-inferiority randomized controlled trial of tranexamic acid (TXA) versus placebo and, using a partial factorial design, of a perioperative hypotension-avoidance versus hypertension-avoidance strategy. The primary objective of the study is to determine; if TXA is superior to placebo for the occurrence of life-threatening, major, and critical organ bleeding, and non-inferior to placebo for the occurrence of major arterial and venous thrombotic event; and to determine the impact of a hypotension-avoidance strategy versus a hypertension-avoidance strategy on the risk of vascular death and major vascular events in patients who are followed for 30 days after noncardiac surgery.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Tranexamic Acid (TXA) | Active Comparator | Patients will receive a 1g loading dose of intravenous TXA before surgery and a 1g loading dose of intravenous TXA at the end of surgery (wound closure). |
|
| Placebo (0.9% normal saline) | Placebo Comparator | Patients will receive a 1g loading dose of placebo (0.9% normal saline) before surgery and a 1g loading dose of placebo (0.9% normal saline) at the end of surgery (wound closure). |
|
| Hypotension-avoidance strategy | Active Comparator | Aims to avoid hypotension before surgery (preoperative), during surgery (intraoperative) and for the first 2 days after the day of surgery (postoperative). |
|
| Perioperative hypertension-avoidance strategy | Placebo Comparator | Aims to avoid hypertension before surgery (preoperative), during surgery (intraoperative) and for the first 2 days after the day of surgery (postoperative). |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Tranexamic Acid | Drug | Within 20 minutes preceding the anticipated skin incision, patients will receive intravenous TXA at a loading dose of 1g over 10 minutes, with a second 1g bolus given at the end of surgery when closing the wound. |
| Measure | Description | Time Frame |
|---|---|---|
| A composite of life-threatening bleeding, major bleeding, and critical organ bleeding | Number of patients who have at least one of the following: life-threatening bleeding, major bleeding, and critical organ bleeding | 30 days after randomization |
| A composite of MINS, non-hemorrhagic stroke, peripheral arterial thrombosis, and symptomatic proximal venous thromboembolism. | Number of patients who have at least one of the following: myocardial injury after noncardiac surgery, non-hemorrhagic stroke, peripheral arterial thrombosis, and symptomatic proximal venous thromboembolism. | 30 days after randomization |
| For patients in the blood pressure management arm: A composite of vascular death, non-fatal MINS, non-fatal stroke, and non-fatal cardiac arrest. | Number of patients enrolled in the blood pressure management arm who have at least one of the following: vascular death, non-fatal myocardial injury after noncardiac surgery, non-fatal stroke, and non-fatal cardiac arrest. | 30 days after randomization |
| Measure | Description | Time Frame |
|---|---|---|
| A net risk-benefit outcome as a composite of vascular death, and non-fatal life-threatening,major or critical organ bleeding,MINS,stroke,peripheral arterial thrombosis,and symptomatic proximal venous thromboembolism | Number of patients who have at least one of the following: vascular death, and non-fatal life-threatening, major or critical organ bleeding, myocardial injury after noncardiac surgery, stroke, peripheral arterial thrombosis, and symptomatic proximal venous thromboembolism, |
| Measure | Description | Time Frame |
|---|---|---|
| Life threatening bleeding | Number of patients who experience a life threatening bleed. | 30 days after randomization |
| Major bleeding | Number of patients who experience a major bleed. |
Inclusion criteria:
A. NT-proBNP ≥200 ng/L B. History of coronary artery disease C. History of peripheral arterial disease D. History of stroke E. Undergoing major vascular surgery; OR F. Any 3 of 9 risk criteria i. Undergoing major surgery; ii. History of congestive heart failure; iii. History of a transient ischemic attack; iv. Diabetes and currently taking an oral hypoglycemic agent or insulin; v. Age >70 years; vi. History of hypertension; vii. Serum creatinine > 175 µmol/L (> 2.0 mg/dl); viii. History of smoking within 2 years of surgery; ix. Undergoing emergent/urgent surgery.
Exclusion criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| PJ Devereaux, MD, PhD | Hamilton Health Sciences Corporation | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Yale New Haven Hospital | New Haven | Connecticut | 06510 | United States | ||
| Cleveland Clinic, Florida |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 40456161 | Derived | Marcucci M, Chan MTV, Painter TW, Efremov S, Aguado HJ, Astrakov SV, Kleinlugtenbelt YV, Patel A, Cata JP, Amir M, Kirov M, Leslie K, Duceppe E, Borges FK, de Nadal M, Tandon V, Landoni G, Likhvantsev VV, Lomivorotov V, Sessler DI, Martinez-Zapata MJ, Xavier D, Fleischmann E, Wang CY, Meyhoff CS, Wittmann M, Torres D, Highton D, Jacka M, B V, Zarnke K, Sidhu RS, Oriani G, Ayad S, Minear S, Weaver TE, Ruetzler K, Brusasco C, Parlow JL, Maxwell E, Miller S, Mrkobrada M, Bhatt KSC, Rahate P, Kowark A, De Blasio G, Ofori SN, Conen D, Srinathan S, Szczeklik W, Jayaram R, Ellerkmann RK, Momeni M, Copland I, Vincent J, Balasubramanian K, Li Z, Wang MK, Li D, McGillion MH, Kurz A, Sharma M, Short TG, Devereaux PJ; cogPOISE-3 Trial Investigators and Study Groups. Effects of a Hypotension-Avoidance Versus a Hypertension-Avoidance Strategy on Neurocognitive Outcomes After Noncardiac Surgery. Ann Intern Med. 2025 Jul;178(7):909-920. doi: 10.7326/ANNALS-24-02841. Epub 2025 Jun 3. | |
| 39813061 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Placebo (Saline) | Drug | Within 20 minutes preceding the anticipated skin incision, patients will receive intravenous placebo (0.9% normal saline) at a loading dose of 1g over 10 minutes, with a second 1g bolus given at the end of surgery when closing the wound. |
|
|
| Perioperative hypotension-avoidance strategy | Other | Perioperative hypotension-avoidance strategy includes:
|
|
| Perioperative hypertension-avoidance strategy | Other | Perioperative hypertension-avoidance strategy (i.e., routine care) continues all antihypertensive drugs before and after surgery and an intraoperative BP strategy targeting a MAP ≥60 mm Hg. |
|
| 30 days after randomization |
| BIMS | Number of patients who experience bleeding independently associated with mortality after noncardiac surgery (BIMS) | 30 days after randomization |
| MINS | Number of patients who experience a myocardial injury after noncardiac surgery (MINS) | 30 days after randomization |
| MINS not fulfilling the universal definition of myocardial infarction | Number of patients who experience a myocardial injury after noncardiac surgery (MINS) not fulfilling the 3rd universal definition of myocardial infarction | 30 days after randomization |
| Myocardial infarction | Number of patients who experience a myocardial infarction | 30 days after randomization |
| For patients in the blood pressure management arm: all-cause mortality | Number of patients who die of any cause | 30 days after randomization |
| For patients in the blood pressure management arm: MINS | Number of patients who experience a myocardial injury after noncardiac surgery (MINS) | 30 days after randomization |
| For patients in the blood pressure management arm: Myocardial infarction | Number of patients who experience a myocardial infarction | 30 days after randomization |
| For patients in the blood pressure management arm: MINS not fulfilling the universal definition of myocardial infarction | Number of patients who experience MINS not fulfilling the universal definition of myocardial infarction | 30 days after randomization |
| 30 days after randomization |
| Critical organ bleeding | Number of patients who experience bleeding in a critical organ. | 30 days after randomization |
| International Society on Thrombosis and Haemostasis (ISTH) major bleeding | Number of patients who experience an International Society on Thrombosis and Haemostasis (ISTH) major bleeding | 30 days after randomization |
| Non-hemorrhagic stroke | Number of patients who experience a non-hemorrhagic stroke | 30 days after randomization |
| Peripheral arterial thrombosis | Number of patients who experience peripheral arterial thrombosis | 30 days after randomization |
| Symptomatic proximal venous thromboembolism | Number of patients who experience a symptomatic proximal venous thromboembolism | 30 days after randomization |
| All-cause mortality | Number of patients who die of any cause | 30 days after randomization |
| Vascular mortality | Number of patients who die of vascular cause | 30 days after randomization |
| Hemorrhagic stroke | Number of patients who experience a hemorrhagic stroke | 30 days after randomization |
| Transfusion rate | Rate of transfusion in patients who experience a major bleeding event | 30 days after randomization |
| Cardiac revascularization | Number of patients who have undergo cardiac revascularization | 30 days after randomization |
| Amputation | Number of patients who have an amputation | 30 days after randomization |
| Symptomatic pulmonary embolism | Number of patients who experience a symptomatic pulmonary embolism | 30 days after randomization |
| Symptomatic proximal DVT | Number of patients who experience a symptomatic proximal DVT | 30 days after randomization |
| Any symptomatic or asymptomatic proximal venous thromboembolism | Number of patients who experience any (symptomatic or asymptomatic) proximal venous thromboembolism | 30 days after randomization |
| Acute kidney injury | Number of patients who experience an acute kidney injury | 30 days after randomization |
| New renal replacement therapy | Number of patients who require new renal replacement therapy | 30 days after randomization |
| Re-hospitalization for vascular reasons | Number of patients who experience a re-hospitalization for vascular reasons | 30 days after randomization |
| Seizures | Number of patients who experience a seizure | 30 days after randomization |
| Infection/sepsis | Number of patients who experience infection/sepsis | 30 days after randomization |
| Disability | Number of patients who experience disability (based on 12-item WHO Disability Assessment Schedule [WHODAS 2.0]). | 30 days after randomization |
| Length of hospital stay | Average length of hospital stay | 30 days after randomization |
| Days alive and at home | Number of days alive and at home | 30 days after randomization |
| For patients in the blood pressure management arm: vascular death | Number of patients who die from a vascular cause | 30 days after randomization |
| For patients in the blood pressure management arm: non-fatal MINS | Number of patients who experience a non-fatal MINS | 30 days after randomization |
| For patients in the blood pressure management arm: non-fatal stroke | Number of patients who experience a non-fatal stroke | 30 days after randomization |
| For patients in the blood pressure management arm: non-fatal cardiac arrest | Number of patients who experience non-fatal cardiac arrest | 30 days after randomization |
| For patients in the blood pressure management arm: hemorrhagic stroke | Number of patients who experience a hemorrhagic stroke | 30 days after randomization |
| For patients in the blood pressure management arm: non-hemorrhagic stroke | Number of patients who experience a non-hemorrhagic stroke | 30 days after randomization |
| For patients in the blood pressure management arm: acute kidney injury | Number of patients who experience an acute kidney injury | 30 days after randomization |
| For patients in the blood pressure management arm: new renal replacement therapy | Number of patients with new requirement for renal replacement therapy | 30 days after randomization |
| For patients in the blood pressure management arm: acute congestive heart failure | Number of patients who experience acute congestive heart failure | 30 days after randomization |
| For patients in the blood pressure management arm: new clinically important atrial fibrillation | Number of patients who experience new clinically important atrial fibrillation | 30 days after randomization |
| For patients in the blood pressure management arm: sepsis | Number of patients who experience a sepsis event | 30 days after randomization |
| For patients in the blood pressure management arm: disability | Number of patients who experience disability (based on 12-item WHO Disability Assessment Schedule [WHODAS 2.0]). | 30 days after randomization |
| For patients in the blood pressure management arm: cancellation/postponement of surgery on the day of surgery due to BP concerns | Number of patients whose surgery was cancelled/postponed on the day of surgery due to BP concerns | 30 days after randomization |
| For patients in the blood pressure management arm: length of hospital stay | Average length of hospital stay required | 30 days after randomization |
| For patients in the blood pressure management arm: days alive and at home | Number of days alive and at home | 30 days after randomization |
| All-cause mortality | Number of patients who die of any cause | 1 year after randomization |
| Vascular mortality | Number of patients who die of vascular cause | 1 year after randomization |
| Myocardial infarction | Number of patients who experience a myocardial infarction | 1 year after randomization |
| Cardiac arrest | Number of patients who experience cardiac arrest | 1 year after randomization |
| Hemorrhagic stroke | Number of patients who experience a hemorrhagic stroke | 1 year after randomization |
| Non-hemorrhagic stroke | Number of patients who experience a non-hemorrhagic stroke | 1 year after randomization |
| Peripheral arterial thrombosis | Number of patients who experience peripheral arterial thrombosis | 1 year after randomization |
| Amputation | Number of patients who had an amputation | 1 year after randomization |
| Symptomatic pulmonary embolism | Number of patients who experience a symptomatic pulmonary embolism | 1 year after randomization |
| Symptomatic proximal DVT | Number of patients who experience a symptomatic proximal DVT | 1 year after randomization |
| Symptomatic proximal venous thromboembolism | Number of patients who experience a symptomatic proximal venous thromboembolism | 1 year after randomization |
| Any symptomatic or asymptomatic proximal venous thromboembolism | Number of patients who experience any symptomatic or asymptomatic proximal venous thromboembolism | 1 year after randomization |
| New renal replacement therapy | Number of patients who require new renal replacement therapy | 1 year after randomization |
| Re-hospitalization for vascular reasons | Number of patients re-hospitalized for vascular reasons | 1 year after randomization |
| Seizures | Number of patients who experience a seizure | 1 year after randomization |
| Infection/sepsis | Number of patients who experience an infection and/or sepsis event | 1 year after randomization |
| Disability | Number of patients who experience disability (based on 12-item WHO Disability Assessment Schedule [WHODAS 2.0]). | 1 year after randomization |
| For patients in the blood pressure management arm: all-cause mortality | Number of patients who die of any cause | 1 year after randomization |
| For patients in the blood pressure management arm: vascular mortality | Number of patients who die of a vascular cause | 1 year after randomization |
| For patients in the blood pressure management arm: myocardial infarction | Number of patients who experience a myocardial infarction | 1 year after randomization |
| For patients in the blood pressure management arm: cardiac arrest | Number of patients who experience cardiac arrest | 1 year after randomization |
| For patients in the blood pressure management arm: hemorrhagic stroke | Number of patients who experience a hemorrhagic stroke | 1 year after randomization |
| For patients in the blood pressure management arm: non-hemorrhagic stroke | Number of patients who experience a non-hemorrhagic stroke | 1 year after randomization |
| For patients in the blood pressure management arm: new renal replacement therapy | Number of patients who require new renal replacement therapy | 1 year after randomization |
| For patients in the blood pressure management arm: acute congestive heart failure | Number of patients who experience acute congestive heart failure | 1 year after randomization |
| For patients in the blood pressure management arm: sepsis | Number of patients who experience a sepsis event | 1 year after randomization |
| For patients in the blood pressure management arm: Disability | Number of patients who experience disability (based on 12-item WHO Disability Assessment Schedule [WHODAS 2.0]). | 1 year after randomization |
| For patients in the blood pressure management arm (CogPOISE-3 Sub study): Delirium | Number of patients who experience delirium (based on 3D-CAM or ICU-CAM) | Post operative day one to three |
| For patients in the blood pressure management arm (CogPOISE-3 Sub study): Cognitive decline | Number of patients who experience cognitive decline (at least 2 points decline on Montreal Cognitive Assessment MoCA) compared to assessment after consent and before randomization | 1 year after randomization |
| Weston |
| Florida |
| 33331 |
| United States |
| Columbia University | New York | New York | 10027 | United States |
| University of North Carolina at Chapel Hill | Chapel Hill | North Carolina | 27599-7010 | United States |
| Wake Forest | Winston-Salem | North Carolina | 27157 | United States |
| Cleveland Clinic - Fairview | Cleveland | Ohio | 44111 | United States |
| Cleveland Clinic - Main Campus | Cleveland | Ohio | 44195 | United States |
| The Ohio State University Wexner Medical Center | Columbus | Ohio | 43210 | United States |
| Cleveland Clinic - Hillcrest | Mayfield Heights | Ohio | 44124 | United States |
| Oregon Health & Science University | Portland | Oregon | 97239 | United States |
| Rhode Island Hospital | Providence | Rhode Island | 02903 | United States |
| MD Anderson Cancer Center | Houston | Texas | 77030 | United States |
| Queen Elizabeth II Jubilee Hospital | Brisbane | Queensland | 4108 | Australia |
| Princess Alexandra Hospital | Woolloongabba | Queensland | Australia |
| Royal Adelaide Hospital | Adelaide | South Australia | Australia |
| Flinders Medical Centre | Bedford Park | South Australia | Australia |
| Royal Hobart Hospital | Hobart | Tasmania | Australia |
| Eastern Health (Box Hill Hospital) | Box Hill | Victoria | Australia |
| Dandenong Hospital | Dandenong | Victoria | Australia |
| Austin Hospital | Heidelberg | Victoria | Australia |
| Royal Melbourne Hospital | Parkville | Victoria | Australia |
| Fiona Stanley Hospital | Murdoch | Western Australia | Australia |
| Western Health | Footscray | Australia |
| Peter MacCallum Hospital | Melbourne | Australia |
| John Hunter Hospital | New Lambton | Australia |
| Royal Perth | Perth | Australia |
| Princes of Wales Hospital | Randwick | Australia |
| Goulburn Valley Health | Shepparton | Australia |
| Westmead Hospital | Sydney | Australia |
| Medical University of Vienna | Vienna | Austria |
| CHU Brugmann | Brussels | Belgium |
| Cliniques Universitaires Saint-Luc | Brussels | Belgium |
| Hospital do Coracao de Pocos de Caldas | Poços de Caldas | Minas Gerais | Brazil |
| Hospital de Clinicas de Porto Alegre | Porto Alegre | Brazil |
| University of Calgary, O'Brien Institute for Public Health | Calgary | Alberta | Canada |
| University of Alberta | Edmonton | Alberta | Canada |
| Health Sciences Centre | Winnipeg | Manitoba | Canada |
| Hamilton General Hospital | Hamilton | Ontario | L8L 2X2 | Canada |
| St. Joseph's Healthcare Hamilton | Hamilton | Ontario | L8N 4A6 | Canada |
| Juravinski Hospital & Cancer Centre | Hamilton | Ontario | L8V 1C3 | Canada |
| Kingston Health Sciences Centre | Kingston | Ontario | Canada |
| University Health Network (Toronto General Hospital) | Toronto | Ontario | Canada |
| CHUM | Montreal | Quebec | Canada |
| Sherbrooke | Sherbrooke | Quebec | Canada |
| Royal University Hospital (Saskatoon) | Saskatoon | Saskatchewan | Canada |
| Victoria Hospital | London | Canada |
| Clinica Santa Maria | Santiago | Chile |
| Hospital Hernan Henriquez | Temuco | Chile |
| Second Hospital of Anhui Medical University | Hefei | Anhui | China |
| Shenzhen People's Hospital | Shenzhen | Guangdong | China |
| The Fourth Affiliated Hospital of Harbin Medical University | Harbin | Heilongjiang | China |
| West China Hospital of Sichuan University | Chengdu | Sichuan | China |
| Bispebjerg Hospital | Copenhagen | Capital Region | Denmark |
| Rigshospitalet, Abdominal Centre | Copenhagen | Denmark |
| Zealand University Hospital | Køge | Denmark |
| Groupe Hospitalier Paris Saint Joseph | Paris | France |
| University Hospital RWTH Aachen | Aachen | Germany |
| University Hospital Bonn | Bonn | Germany |
| Klinikum Dortmund gGmbH | Dortmund | Germany |
| University Hospital Düsseldorf | Düsseldorf | Germany |
| Prince of Wales Hospital | Shatin | Hong Kong |
| Surat Institute of Digestive Science | Surat | Gujarat | India |
| Sumandeep Vidyapeeth & Dhiraj General Hospital | Vadodara | Gujurat | India |
| Nanjappa Hospital | Shimoga | Karnataka | India |
| Government Medical College | Trivandrum | Kerala | 695011 | India |
| Rahate Surgical Hospital | Nagpur | Maharashtra | India |
| Sengupta Hospital & Research Institute | Nagpur | Maharashtra | India |
| AMAI Charitable Trust's Ace Hospital | Pune | Maharashtra | India |
| Sidhu Hospital Pvt. Ltd. | Dorāha | Punjab | India |
| Christian Medical College, Ludhiana | Ludhiana | Punjab | India |
| Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow | Lucknow | Uttar Pradesh | India |
| NH Rabindranath Tagore International Inst. of Cardiac Sciences | Kolkata | West Bengal | 700099 | India |
| TD Medical College | Alappuzha | India |
| Bangalore Baptist Hospital | Bangalore | India |
| Ospedale Galliera di Genova | Genova | Italy |
| Instituto Clinico San Siro | Milan | Italy |
| IRCCS San Raffaele Scientific Institute | Milan | Italy |
| IRCCS Galeazzi Orthopedic Institute | Milan | Italy |
| Port Dickson Hospital | Port Dickson | Negeri Sembilan | Malaysia |
| Sarawak General Hospital | Kuching | Sarawak | Malaysia |
| Hospital Kuala Lumpur | Kuala Lumpur | Malaysia |
| University Malaya Medical Centre | Kuala Lumpur | Malaysia |
| Hospital Pulau Pinang | Pulau Pinang | Malaysia |
| Sungai Buloh Hospital | Sungai Buloh | Malaysia |
| Deventer Ziekenhuis | Deventer | Overijssel | Netherlands |
| Erasmus University Medical Center | Rotterdam | Netherlands |
| Auckland General Hospital | Grafton | Auckland | New Zealand |
| Middlemore Hospital | Auckland | New Zealand |
| Waikato District Health Board | Hamilton | New Zealand |
| Shifa International Hospitals | Islamabad | Islamabad | Pakistan |
| Aga Khan University | Karachi | Pakistan |
| Jagiellonian University Medical College | Krakow | Poland |
| Specialistyczny Szpital im. E. Szczeklika w Tarnowie | Tarnów | Poland |
| Szpital Uniwersytecki im Karola Marcinkowskiego w Zielonej Górze | Zielona Góra | Poland |
| City Hospital 1 of Arkhangelsk | Arkhangelsk | Russia |
| V. Negovskiy Reanimatology Research Institute | Moscow | 107031 | Russia |
| Moscow Regional Research & Clinical Institute (MONIKI) | Moscow | Russia |
| City Hospital N25 | Novosibirsk | Russia |
| E. Meshalkin National Medical Research Center | Novosibirsk | Russia |
| Hospital of Saint-Petersburg State University | Saint Petersburg | Russia |
| Tyumen State Medical University | Tyumen | Russia |
| Groote Schuur Hospital | Observatory | Cape Town | South Africa |
| Sefako Makgatho Health Sciences University (SMU) | Ga-Rankuwa | Gauteng | South Africa |
| Steve Biko Academic Hospital - University of Pretoria | Pretoria | Gauteng | South Africa |
| Hospital Clinic - Barcelona | Barcelona | Spain |
| Hospital de la Sta Creu i Sant Pau | Barcelona | Spain |
| Hospital Vall D'Hebron | Barcelona | Spain |
| Hospital Dr. Josep Trueta | Girona | Spain |
| Hospital Ramon y Cajal | Madrid | Spain |
| Hospital Universitario Fundacion Alcorcon | Madrid | Spain |
| Hospital Clínico Universitario in Valladolid | Valladolid | Spain |
| Medway NHS Foundation Trust | Gillingham | United Kingdom |
| Chelsea & Westminster Hospital | London | United Kingdom |
| West Middlesex Hospital | London | United Kingdom |
| Derived |
| Park LJ, Marcucci M, Ofori SN, Borges FK, Nenshi R, Kanstrup CTB, Rosen M, Landoni G, Lomivorotov V, Painter TW, Xavier D, Martinez-Zapata MJ, Szczeklik W, Meyhoff CS, Chan MTV, Simunovic M, Bogach J, Serrano PE, Balasubramanian K, Cadeddu M, Yang I, Kim WH, Devereaux PJ. Safety and Efficacy of Tranexamic Acid in General Surgery. JAMA Surg. 2025 Mar 1;160(3):267-274. doi: 10.1001/jamasurg.2024.6048. |
| 39490985 | Derived | POISE-3 Trial Investigators and Study Groups. A sub-study of the POISE-3 randomized trial examined effects of a perioperative hypotension-avoidance strategy versus a hypertension-avoidance strategy on the risk of acute kidney injury. Kidney Int. 2025 Jan;107(1):155-168. doi: 10.1016/j.kint.2024.10.007. Epub 2024 Oct 25. |
| 37094336 | Derived | Marcucci M, Painter TW, Conen D, Lomivorotov V, Sessler DI, Chan MTV, Borges FK, Leslie K, Duceppe E, Martinez-Zapata MJ, Wang CY, Xavier D, Ofori SN, Wang MK, Efremov S, Landoni G, Kleinlugtenbelt YV, Szczeklik W, Schmartz D, Garg AX, Short TG, Wittmann M, Meyhoff CS, Amir M, Torres D, Patel A, Ruetzler K, Parlow JL, Tandon V, Fleischmann E, Polanczyk CA, Lamy A, Jayaram R, Astrakov SV, Wu WKK, Cheong CC, Ayad S, Kirov M, de Nadal M, Likhvantsev VV, Paniagua P, Aguado HJ, Maheshwari K, Whitlock RP, McGillion MH, Vincent J, Copland I, Balasubramanian K, Biccard BM, Srinathan S, Ismoilov S, Pettit S, Stillo D, Kurz A, Belley-Cote EP, Spence J, McIntyre WF, Bangdiwala SI, Guyatt G, Yusuf S, Devereaux PJ; POISE-3 Trial Investigators and Study Groups. Hypotension-Avoidance Versus Hypertension-Avoidance Strategies in Noncardiac Surgery : An International Randomized Controlled Trial. Ann Intern Med. 2023 May;176(5):605-614. doi: 10.7326/M22-3157. Epub 2023 Apr 25. |
| 35363452 | Derived | Devereaux PJ, Marcucci M, Painter TW, Conen D, Lomivorotov V, Sessler DI, Chan MTV, Borges FK, Martinez-Zapata MJ, Wang CY, Xavier D, Ofori SN, Wang MK, Efremov S, Landoni G, Kleinlugtenbelt YV, Szczeklik W, Schmartz D, Garg AX, Short TG, Wittmann M, Meyhoff CS, Amir M, Torres D, Patel A, Duceppe E, Ruetzler K, Parlow JL, Tandon V, Fleischmann E, Polanczyk CA, Lamy A, Astrakov SV, Rao M, Wu WKK, Bhatt K, de Nadal M, Likhvantsev VV, Paniagua P, Aguado HJ, Whitlock RP, McGillion MH, Prystajecky M, Vincent J, Eikelboom J, Copland I, Balasubramanian K, Turan A, Bangdiwala SI, Stillo D, Gross PL, Cafaro T, Alfonsi P, Roshanov PS, Belley-Cote EP, Spence J, Richards T, VanHelder T, McIntyre W, Guyatt G, Yusuf S, Leslie K; POISE-3 Investigators. Tranexamic Acid in Patients Undergoing Noncardiac Surgery. N Engl J Med. 2022 May 26;386(21):1986-1997. doi: 10.1056/NEJMoa2201171. Epub 2022 Apr 2. |
| 35101083 | Derived | Marcucci M, Painter TW, Conen D, Leslie K, Lomivorotov VV, Sessler D, Chan MTV, Borges FK, Martinez Zapata MJ, Wang CY, Xavier D, Ofori SN, Landoni G, Efremov S, Kleinlugtenbelt YV, Szczeklik W, Schmartz D, Garg AX, Short TG, Wittmann M, Meyhoff CS, Amir M, Torres D, Patel A, Duceppe E, Ruetzler K, Parlow JL, Tandon V, Wang MK, Fleischmann E, Polanczyk CA, Jayaram R, Astrakov SV, Rao M, VanHelder T, Wu WKK, Cheong CC, Ayad S, Abubakirov M, Kirov M, Bhatt K, de Nadal M, Likhvantsev V, Iglesisas PP, Aguado HJ, McGillion M, Lamy A, Whitlock RP, Roshanov P, Stillo D, Copland I, Vincent J, Balasubramanian K, Bangdiwala SI, Biccard B, Kurz A, Srinathan S, Petit S, Eikelboom J, Richards T, Gross PL, Alfonsi P, Guyatt G, Belley-Cote E, Spence J, McIntyre W, Yusuf S, Devereaux PJ. Rationale and design of the PeriOperative ISchemic Evaluation-3 (POISE-3): a randomized controlled trial evaluating tranexamic acid and a strategy to minimize hypotension in noncardiac surgery. Trials. 2022 Jan 31;23(1):101. doi: 10.1186/s13063-021-05992-1. |
| ID | Term |
|---|---|
| D020246 | Venous Thrombosis |
| D007022 | Hypotension |
| D006973 | Hypertension |
| ID | Term |
|---|---|
| D013927 | Thrombosis |
| D016769 | Embolism and Thrombosis |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D014148 | Tranexamic Acid |
| D012965 | Sodium Chloride |
| ID | Term |
|---|---|
| D003509 | Cyclohexanecarboxylic Acids |
| D000146 | Acids, Carbocyclic |
| D002264 | Carboxylic Acids |
| D009930 | Organic Chemicals |
| D002712 | Chlorides |
| D006851 | Hydrochloric Acid |
| D017606 | Chlorine Compounds |
| D007287 | Inorganic Chemicals |
| D017670 | Sodium Compounds |
Not provided
Not provided